LSTA

Lisata Therapeutics, Inc. (LSTA) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors by activating the CendR active transport pathway. The company is currently conducting Phase 2 clinical studies for certepetide in various solid tumors, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, and glioblastoma multiforme.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 10.5% in Q3 2024 compared to Q3 2023 ($5.3M vs. $6.0M). This was driven primarily by a 24.8% decrease in R&D expenses ($2.5M vs. $3.4M), attributed to reduced Clinical Research Organization (CRO) costs for the Bolster trial and lower equity-based compensation. G&A expenses increased slightly by 8.1% due to higher consulting fees.
• Liquidity Decline: Total liquidity (cash and marketable securities) decreased from approximately $50.5 million at the end of Q3 2023 to $35.9 million at the end of Q3 2024. This reflects a net cash burn of approximately $14.8 million from operations over the nine-month period, partially offset by net sales of marketable securities ($11.8M provided by investing activities).
• Investment Income: Investment income decreased to $451k in Q3 2024 from $714k in Q3 2023, reflecting lower balances in marketable securities.
• Legal Settlement: In March 2024, the company settled a legal dispute with Lingmed Limited for $0.5 million, with additional contingent payments tied to future milestones.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash and marketable securities ($35.9M) are sufficient to fund operations for at least the next 12 months. The company is exploring additional capital sources, including equity/debt issuances, partnerships, and grants.
• ATM Facility: The company has an "At The Market" (ATM) offering agreement. Due to the "Baby Shelf Limitation" (public float below $75M), the company is currently limited to selling securities up to one-third of its public float. As of August 2024, this limit was approximately $9.9 million. No shares were issued under the ATM in the first nine months of 2024.
• Risks: Key risks include the inability to raise additional capital on acceptable terms, delays in clinical trials (patient enrollment, regulatory approvals), and the uncertainty of commercializing certepetide. The company has no revenue and relies entirely on financing and investment income.
• Tax Incentives: The company received a $0.9 million tax refund from the Australian Taxation Office in July 2024 and sold New Jersey Net Operating Losses (NOLs) for net proceeds of $0.7 million in March 2024.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the 12-month liquidity projection given the current burn rate of ~$5M per quarter.
• Clinical Trial Progress: Monitor enrollment and data readouts for the Phase 2 trials in mPDAC, cholangiocarcinoma, and glioblastoma, as these are critical for future valuation and funding.
• Capital Raising Constraints: Assess the impact of the "Baby Shelf Limitation" on the company's ability to raise capital quickly via the ATM facility if market conditions deteriorate.
• Legal Contingencies: Review the terms of the Lingmed settlement, specifically the 5% royalty on future milestones and the $250k payment on the first milestone, which could impact future cash flows from the Qilu license agreement.
• Equity Dilution: Track the volume of share-based compensation and potential future equity issuances required to fund operations.